Summary
This clinical trial is comparing Petosemtamab, which is an experimental bispecific antibody, with the Investigator's choice of treatment in people with head and neck squamous cell carcinoma (HNSCC) as a second- and third-line treatment for their incurable metastatic or recurrent disease.
To be eligible, people with HNSCC must have progressive disease (PD) on or after anti-PD-1 therapy and platinum-containing therapy. People treated with platinum-containing therapy only in the adjuvant setting, or in the context of multimodal therapy for locally advanced disease, should have PD within 6 months of the last dose of platinum-containing therapy.
Eligible participants will be randomly allocated to one of two treatment arms.
In the Experimental Arm, participants will receive Petosemtamab.
In the Active Comparator Arm, participants will receive the Investigator's choice of either:
- Cetuximab targeted therapy,
- Methotrexate chemotherapy or
- Docetaxel chemotherapy